摘要
目的分析中药复方肝癌-1号逆转阿霉素(ADM)诱导的HepG2/ADM细胞的多药耐药性的机制。方法以亲本细胞HepG2为对照,MTT法观察肝癌-1号对HepG2/ADM细胞的毒性作用;流式细胞仪检测肝癌-1号作用后细胞表面p-糖蛋白(P-gp)表达阳性率;逆转录聚合酶链式反应检查多药耐药基因(MDR1)mRNA表达水平;MTT法观察肝癌-1号处理后的HepG2/ADM细胞对阿霉素、表阿霉素、氟尿嘧啶耐药的逆转作用。结果肝癌-1号<50μmol/L对HepG2/ADM细胞无明显毒性,半数抑制率(IC50)为75μmol/L;50μmol/L的肝癌-1号可部分抑制HepG2/ADM细胞P-gp合成及MDR1 mRNA的表达,可逆转HepG2/ADM的耐药性,对阿霉素、表阿霉素、氟尿嘧啶的逆转倍数分别为3.94(P<0.01),1.72(P<0.05),1.67(P<0.05)。结论肝癌-1号通过抑制HepG2/ADM耐药细胞MDR1 mRNA的表达及P-gp合成,能部分逆转HepG2/ADM的耐药性。
Objective To explore the effects of GanAi 1 on the reversal of muhidrug resistance （MDR） in HepG2/ADM cells induced by adriamyein （ADM）. Methods HepG2 cells served as control. The eytotoxieity of GanAi-1 on HepG2/ADM cells was determined by MTT assay. The expression of p-glycoportein （P gp） and MDR1 mRNA was measured by flow cytometric assay or RT-PCR, respectively. The effects of GanAi-1 on ADM, Epirubiein and Fluoroplex mediated drug resistance were observed by MTT assay. Results GanAi 1 less than 50μmol/L had no significant influence on the cytotoxicity of HepG2/ADM cells, and the IC50 was 75μmol/L. After exposure to 50μmol/L GanAi-1, the P gp protein and MDR1 mRNA expression in HepGz/ADM cells decreased partially. Simultaneously, ADM, Epirubicin and Fluoroplex resistance in HepG2/ADM cells was reversed by a factor of 3.94 （ P 〈0. 01）, 1. 72 （ P 〈0. 05） and 1. 67 （ P〈0. 05）, respectively. Conclusions GanAi-1 can partially reverse the MDR of HepG2/ADM cells through inhibiting the expression of P-gp protein and MDR1 mRNA.
出处
《消化外科》
CSCD
2006年第1期70-73,共4页
Journal of Digestive Surgery
基金
重庆市卫生局资助项目(渝卫科教[2002]01-2-01)
关键词
肝肿瘤
中药
多药耐药
复方肝癌-1号
hepatic tumor
Chinese Tranditional Medicine
multidrug resistance
GanAi-1
